# Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLC

> **NCT04683198** · PHASE2 · UNKNOWN · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 69 (estimated)

## Conditions studied

- Small-cell Lung Cancer

## Interventions

- **DRUG:** camrelizumab
- **DRUG:** Apatinib Mesylate
- **DRUG:** Carboplatin
- **DRUG:** Etoposide

## Key facts

- **NCT ID:** NCT04683198
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-01
- **Primary completion:** 2023-10-30
- **Final completion:** 2024-06-30
- **Target enrollment:** 69 (ESTIMATED)
- **Last updated:** 2020-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04683198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04683198, "Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLC". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04683198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*